Lv4
428 积分 2022-12-30 加入
Sue Zupanec et al. Navigating B-ALL in the Era of blinatumomab. Am Soc Clin Oncol Educ Book 45, e472778(2025)
6个月前
已关闭
Up-front Blinatumomab Improves MRD Clearance and Outcome in Adult Ph− B-lineage ALL: the GIMEMA LAL2317 Phase 2 Study
9个月前
已关闭
Up-front Blinatumomab Improves MRD Clearance and Outcome in Adult Ph− B-lineage ALL: the GIMEMA LAL2317 Phase 2 Study
9个月前
已关闭
Shorter Duration of Blinatumomab Administration to 14 Days Has Same Efficacy and Safety Profile in Treatment of Relapsed/Refractory B-Cell Precursor Acute Lymphoblastic Leukemia: A Retrospective Single‐Center Study
11个月前
已关闭
Comparison of progression risk of monoclonal gammopathy of undetermined significance by method of detection
1年前
已关闭
Philadelphia-like B-cell acute lymphoblastic Leukaemia: Disease features and outcomes in the era of immunotherapy
1年前
已完结
NGS-based stratification refines the risk stratification in T-ALL and identifies a very-high-risk subgroup of patients
1年前
已完结
How I Treat Older Patients with Ph/BCR-ABL-Negative Acute Lymphoblastic Leukemia
1年前
已关闭
How I use next-generation sequencing–MRD to plan approach and prevent relapse after HCT for children and adults with ALL
1年前
已完结
How I Use Next Generation Sequencing-MRD to Plan Approach and Prevent Relapse after HCT for Children and Adults with ALL
1年前
已关闭
皖公网安备34019202002308
